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Background: A systematic literature review of the last 40 years on the research of serum antibodies to Pseudomonas aeruginosa in cystic ﬁbrosis
and its utility as a diagnostic tool.
Methods: Research papers in English, Portuguese, and Spanish were accessed through electronic databases (PubMed, Medline, LILACS, and
SciELO).
Results: 26 studies were assessed. ELISA technique was the most commonly used technique to detect serum P. aeruginosa antibodies. The most
consistent results were those in which the response against the antigen St-Ag:1–17 was evaluated. The accuracy levels of the ELISA technique
remain controversial, but most studies showed a good correlation between antibody titers and microbiological culture.
Conclusions: The detection of serum antibodies to P. aeruginosa shows capacity for early detection of this pathogen and potential utility and
viability of incorporation in the diagnostic routine of patients with cystic ﬁbrosis.
© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Pseudomonas aeruginosa; Cystic ﬁbrosis; Serum antibodies; Review
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Pseudomonas aeruginosa pulmonary infection is responsi-
ble for elevated morbidity and mortality among cystic fibrosis
(CF) patients [1,2]. In childhood, 10 to 30% of these patients
are colonized and in adulthood, 80 to 90% are infected with
this bacterium. Patients infected with P. aeruginosa generally
present a reduction of about 10 years in life expectancy when
compared with the non-infected ones [3].
When chronic infection [4] is established, P. aeruginosa is
practically impossible to be eradicated [1,2], although, its clearance
from the respiratory tract is possible through early intervention
with antibiotic therapy, as soon as the pathogen settles in the
organism. Thus, early aggressive treatment is recommended, being
possible to delay the chronic colonization and progression of the
pulmonary disease [5].
Detection of P. aeruginosa in the diagnostic routine is made
mostly through sputum culture — spontaneously expectorated or
induced by inhalation of hypertonic saline (3–7%); however, many
patients – especially children under 7 years – are incapable of
producing an expectorated sputum specimen. BAL, the gold
standard, is an option, but it is invasive and usually employed only
when there is a compelling reason to obtain a respiratory sample
and other approaches have failed. For this reason, oropharyngeal
(OP) swabs are used as a surrogate for sputum or BAL fluid
specimens in these individuals, sampling the microbial flora of the
upper respiratory tract, which is assumed to reflect that of the lower
respiratory tract [6]. Despite the good specificity reported for this
method, in comparison to BAL culture, it is known that a negative
culture from the upper airways does not exclude the presence of
P. aeruginosa in the lower airways [7,8]. Sampling errors during
the BAL and the frequent insufficient sample obtained through
oropharyngeal swab can lead to false negative results [7]. The
difficulty in obtaining representative respiratory specimens from
the airways of infants and children indicates the need for the use of
methods that can complement or be an alternative to microbiolog-
ical culture [9].
The detection of serum antibodies against P. aeruginosa
has emerged as a possible auxiliary method to assess the early
eradication therapy [10,11]. Highly sensitive methods for
detection of antibodies against several P. aeruginosa antigens
may complement the monitoring methods currently used [11].
Positive antibody titer results and culture-negative samples of
respiratory secretion should alert health professionals to perform a
more thorough search for a probable infection, by repeating the
test or by using more sensitive and specific methods. In contrast,
increasing antibody levels are associated with a greater likelihood
of persistent P. aeruginosa chronic infection [9]. Elevated
antibody titers at the time of initial OP culture may be a useful
tool for CF clinicians and researchers monitoring patients at
risk for subsequent infection. However, their use in routine
practice remains controversial [9].
Thus, the aim of this systematic review was to collect studies
published in the last 40 years addressing the detection of serum
antibodies to P. aeruginosa and to evaluate its utility for early
detection of this bacterium and the diagnostic and prognostic
value in CF patients.2. Methods
Research papers in English, Portuguese, and Spanish in the
period from 1973 to 2013 were reviewed. The search for
references was made through electronic database exploration
(PubMed, Medline, LILACS and SciELO), using the keywords
“Cystic Fibrosis”, “Pseudomonas aeruginosa”, “serology”, and
“serum antibodies”, and their correspondent translations in varied
combinations, from November to August of 2013. In addition, the
references of all papers were consulted in the search of new papers
to include.
Then, we began the paper selection process, by reviewing titles
and abstracts. The first inclusion criterion was the identification of
potentially relevant papers, considering those in which the study
assessed the utility of serum antibody detection in the diagnostic
routine of pulmonary disease. The recuperation criteria for com-
plete papers were the following types of study: cohort, longitudi-
nal, case–control, descriptive, experimental and cross-sectional,
whose results addressed such subject. The selection was based on
the limits of the compliance of issues in relation to objectives,
excluding those in which, despite appearing in the search results,
did not address the issue from the diagnostic point of view of serum
antibody detection. We also excluded review articles, studies
addressing the immune response to P. aeruginosa but not related to
CF, or related to CF but without clinical application or applied to
the diagnosis and studies not related to the CF pulmonary disease.
3. Data synthesis
3.1. Studies addressed, casuistries and methods used
In the first search, a total of 29 research papers were found,
being submitted to a filter process, from which only the papers
that could be fully accessed were selected. The review was
finished by reading the complete papers and, in the final text,
25 papers were included. The studies were mostly longitudinal
[13,14,19,21,28,30,35,37] and experimental [16,18,23,26,32–34],
and there were also prospective [12,15,16], case–control [27],
cohort [20,23,29] and cross-sectional studies [21,30,36]; all of
them were in English (Table 1).
In the last 40 years, a total of 3148 patients were evaluated,
aged from 0 to 65 years of age, and seven of the studies did not
specify their age range (Table 2). With regard to the diagnostic
method (Table 3), the ELISA technique was the most commonly
used method (22 studies), followed by CIE (5 studies), Western
blot (5 studies), and RIA (one study). Five studies used more than
one method. Different antigens were used, being Exotoxin A
(ExoA) the most used (13 studies), followed by Elastase (ELA) (10
studies), St-Ag:1–17 (Statens Serum Institute®) (8 studies),
Alkaline protease (AP) (8 studies), Lipopolysaccharides (LPS) (3
studies), and other antigens in 8 studies (Table 2). Six studies used
the M-15 kit (Mediagnost®)— ExoA, ELA, and AP.
3.2. Diagnostic and prognostic value
The pioneer studies on serological diagnosis of P. aeruginosa
infection in CF patients date from the 70s by Høiby et al. [12],
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(precipitins) of CIE. In a 5-year follow-up of 133 patients,
high precipitin titers and rapid increase of these were associated
with the worst prognostic, which was corroborated by Döring et al.
[13], who found a higher precipitin production when mucoid
P. aeruginosa persisted in the lungs, leading to a higher formation
of immunocomplexes.
In the 80s, the ELISA technique was included using great
antigen diversity. Overall, there was a significant correlation
between ELISA and CIE results [13,16,18].
Brett et al. [14] observed higher antibody titers in chronically
infected than in intermittent patients, with an overlap between the
two groups. However, higher titers against ExoA, ELA, and AP
(relative to phospholipase C) were observed among patients
colonized/infected with mucoid P. aeruginosa than among patients
who only presented non-mucoid P. aeruginosa. Burns et al. [20]
searched for IgG antibodies against P. aeruginosa through ExoA
ELISA and Western blot for the whole cell antigens. By sputum
culture, only 45% of patients would be considered to be infected,
while antibody detection elevated this percentage to 97.5%. Da
Silva Filho et al. [30] analyzed the serology utility (E-15 kit —
Mediagnost®) for 87 patients, comparing with PCR and culture,
including 16 patients with negative culture, 20 intermittently
colonized and 51 chronically infected patients. They found that the
association of the three methods provided the highest positivity
percentage (PCR with the higher one), but had no statistical
significance. Weisner et al. [28] studied the utility of ELISA
for P. aeruginosa anti-LPS band A antibodies in oral fluids
compared with serum samples in patients with positive culture for
P. aeruginosa and healthy volunteers. They found significant titers
in the oral fluids in 15 of the 17 CF patients and in all serum
samples, but in none of the volunteers. Doğru et al. [37] showed
significant higher antibody titers against ExoA, ELA and AP in
patients colonized with mucoid P. aeruginosa. The antibody
presence showed varied values, with ELA antibodies presenting
the higher titers.
3.3. Early detection of the P. aeruginosa infection
Brett et al. [17], in another ELISA study (for antibodies
against cell wall antigens), observed an enhancement in IgG
levels until 24.5 months before the first bacterial isolation in
culture. Kronborg et al. [19] showed an increase in the serum
IgG, IgM and IgA responses to the lipid A, R-LPS, and S-LPS
antigens during the chronic infection course, mainly IgG and
IgA. Moss et al. [21] found the presence of antibodies against
the TTSS proteins in adult CF patients through Western blot.
About 70% patients had anti-PopD IgG, 90% had anti-PopB
IgG, and 67% had anti-PcrV IgG. The humoral immune response
also showed anti-ExoS IgG in about 33% of the cases, and
anti-ExoA IgG in 73% of patients. There were evidences that
humoral immune response was early for the TTSS components,
during the initial stage of infection, as shown by other two studies
[24,28,36], being the response to TTSS antigens earlier than to
ExoA and PAO1 cell lysate, and the pathogen being found in
a mean time of 21 months before the first isolation in the
microbiological culture.West et al. [22] reported a 15-year longitudinal monitoring of
antibody response (IgG, IgM e IgA) against several P. aeruginosa
antigens in sera of 68 patients, detecting the bacterium up to
12 months before the first isolation. Significant titers of anti-cell
lysate and anti-ExoA antibodies were detected before or simul-
taneous to the first P. aeruginosa isolation in about 60% of the
patients, and antibody titers against ELA were detected until about
40 months after the first isolation.
Pressler et al. [27] followed 89 patients free of infection in a
period of 10 years and found 28 patients that acquired chronic
infection despite of early antibiotic treatment. This group was
compared with 28 patients who did not acquire chronic
infection and it was observed that specific P. aeruginosa IgG
antibodies were significantly higher in the cases than in the
control group until three years before the acquisition of chronic
infection, but remained at the initial levels in the control group.
Later, Pressler et al. [32], following 791 patients, found that, out of
381 patients cultured negative for P. aeruginosa, 11 changed status
to chronically infected and 24 out of 129 intermittently colonized
became chronically infected. The antibody titers in this latter
group were significantly higher at the study start and increased
significantly during the study period. Elevated levels of specific
anti-pseudomonal antibodies showed to be the risk factor for
developing chronic infection.
Tramper-Standers et al. [26], in a longitudinal study, using
microbiological culture as reference, monitored the IgG response to
ExoA, ELA andAP of 220 patients during three consecutive years,
performing serological tests annually. All the three individual
serological tests discriminated well between the absence and
presence of chronic P. aeruginosa colonization.
In 2010, Hayes et al. [33] published a longitudinal 6-year study
that followed 69 children from the CF diagnosis by neonatal
screening. They used serology for anti-cell lysate, ExoA and ELA
antibodies. By establishing cut-offs according to the age of
the patients, they could early identify P. aeruginosa until 2 years
before the detection in microbiologic culture.
Anstead et al. [35], using five antigens and two different
ELISA tests, found, in recently P. aeruginosa colonized
children, that baseline positive serology was not significantly
associated with failure in bacterial eradication with previous
treatment for 10 weeks, but seropositivity to AP and ExoA
was significantly associated with increased risk of recurrent
isolation 60 weeks after eradication. There was no associa-
tion between baseline seropositivity and time to pulmonary
exacerbation.
3.4. Antibody titers and clinical status
Correlation between antibody titers and clinical status was
showed by Høiby et al. [12], which found lower ventilatory
function, severe radiographic alterations and worst prognosis
associated with high P. aeruginosa precipitin levels. Brett et
al. [17] observed a correlation between worst Shwachman–
Kulczyky and Chrispin–Norman scores and enhancement of
IgG antibodies against P. aeruginosa in intermittent and
chronic patients. West et al. [22] performed chest radiographies
at each six months for children under 3 years old and annually
Table 1
Study index, according to author, design, local, objective and results obtained.
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injuries occurred until 5.8 months before the first positive
culture, period that was similar to the appearance of anti-ExoA
antibodies.3.5. Antibody response against the infection treatment
Brett et al. [14] observed a considerable variation in IgG
titers among CF patients, which decreased after i.v. antibiotic
Table 1 (continued)
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in patients in which antibiotic therapy was well succeeded. Of
15 patients who received i.v. antimicrobial therapy, in 5 bacterial
eradication and return of the antibody titers to the normal values
were observed, while in 10, continuous isolations occurred, besides
partial decrease of the titers. Johansen et al. [23] found a decrease in
the precipitin levels during the period of most intensive i.v.
antibiotic therapy regimens, and considerably enhanced survival
(after the acquisition of chronic infection). Ratjen et al. [29], with
a longitudinal evaluation of antibody titers, before and after
inhalatory antibiotic therapy in patients with the first P. aeruginosa
isolate, showed a significant reduction in the titers of patients
clearing P. aeruginosa infection, while there was increased titers in
patients in which eradication therapy failed. Just one study [15] did
not observe significant decrease in antibody titers after antibiotic
therapy against the evaluated antigens.
3.6. Accuracy
Eight studies evaluated the accuracy of serology (ELISA) for
different antigens in regard to different patterns used (Table 4).Pedersen et al. [16], evaluating 243 patients, found a sensitivity of
93% and specificity of 92% for ELISA when compared to CIE,
obtaining a correlation among results of bothmethods. In advanced
stages of infection, the sensitivity was 90% and the specificity was
100%. Kappler et al. [25], in a prospective study with 183 negative
cultured, intermittent and chronic patients, reported that the
antibody detection against three antigens (ExoA, ELA, AP)
resulted in a sensitivity of 86%, specificity of 96% and PPV of
97%, in regard to microbiologic culture. Tramper-Stranders et al.
[26] studied 67 patients chronically infected, 60 intermittently
colonized and 93 non-colonized with P. aeruginosa. The ELISA
tests (ExoA, ELA, and AP) using advised cut-off values had
a sensitivity of 79% and a specificity of 89% for chronic
colonization. Applying new ROC curves to optimize the cut-off
values, they obtained a sensitivity of 96% and a specificity of 79%
(when all three antigens were evaluated together).
Ratjen et al. [29], studying the response to ExoA, ELA, and
AP in 375 patients (and a cohort of 56 patients under antibiotic
therapy), observed individual variability in the antibody titers
against ExoA, ELA and AP, with good sensitivity and specificity
for all the three antigens.
Table 2
Studies listed by number of subjects, age range, methods and antigens used.
Study n Age range (years) Method Antigen
Høiby et al. [12]  133 NE 1 CIE St-Ag:1 –173
Doring et al. [13] 10 8,0 – 29,0 aCIE and bRIA aSt-Ag:1 –172, bAP and ELA 
Brett et al. [14] 75 1,0 – 25,0 ELISA Cell wall antigens
Hollsing et al. [15] 62 0,32 – 32,0 ELISA ExoA, AP, ELA and phospholipase C 
Pedersen et al. [16] 243 NE 1 ELISA and CIE St-Ag:1 –172
Brett et al. [17] 33 0,8 – 27,0 ELISA Cell wall antigens
Formsgaard et al. [18] 10 NE1 aELISA, bCIE and cWestern blot aLPS, bSt-Ag:1 –172 and cLPS
Kronborg et al. [19] 12 1,0 – 15,0 ELISA Different LPS types
Burns et al. [20] 42 2,5 – 15,5 ELISA ExoA in house 
Moss et al. [21] 33 NE 1 Western blot TTSS proteins
West et al. [22] 68 NE 1 ELISA Cell lysate, ELA and ExoA
Johansen et al. [23] 157 NE1 CIE St-Ag:1 -172
Corech et al. [24] 48 NE1 ELISA and Western blot ExoA, cell lysate and TTSS proteins 
Kappler et al. [25] 183 2,0 – 38,0 ELISA ExoA, ELA and AP3
Tramper-Standers et al. [26] 220 0,0 – 65,0 ELISA ExoA, ELA and AP3
Pressler et al. [27] 89 NE1 ELISA St-Ag:1 –17
Weisner et al. [28] 17 NE1 ELISA and Western blot LPS
Ratjen et al. [29] 375 1,0 – 52,0 ELISA ExoA, ELA and AP3
Da Silva Filho et al. [30]  87 0,24 – 19,0 ELISA ExoA, ELA and AP3
Milagres et al. [31] 51 1,1 – 16,8 ELISA Cell lysate and recombinant PcrV
Pressler et al. [32] 719 NE1 aELISA and bCIE aExoA and a,bSt-Ag:1 –172
Hayes et al. [33] 69 NE1 ELISA Cell lysate, ExoA and ELA
Douglas et al. [34] 131 0,1 – 7,1 ELISA 2St-Ag:1 –17 and ExoA in house
Anstead et al. [35] 303 1,0 – 12,0 ELISA ExoA, ELA, AP3 and MCW antigens4
Cruz et al. [36] 27 2,5 -16,8 Western blot TTSS proteins
Doğru et al. [37] 90 0,64 – 26,3 ELISA ExoA, ELA and AP3
1 Non specified.
2 Antigen commercialized by Statens Serum Institute® (Copenhagen, Denmark).
3 ExoA, AP and ELA (M-15 kit) – antigens commercialized by Mediagnost® (Reutlingen, Germany).
4 Antigens produced by the Medical College of Wisconsin (MCW): ExoS+PopB, Cell lysate PAO1 and ExoA.
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serological methods most used in the CF follow-up routine and
their usefulness in early chronic P. aeruginosa detection. They
studied 381 patients free of infection, 129 intermittent colonized
and 281 chronically infected. The values encountered showed high
sensitivity, specificity, PPV and NPV (about 90%) for all methods.
Douglas et al. [34] compared two serological methods (anti-IgG
ELISA of the Copenhagen group and an anti-ExoA in-house
ELISA) between two CF populations in Australia. They observed
high PPVs, but low NPVs in both populations, in regard to BAL
culture (used as gold standard in the study) — respectively, 14%
and 26% for the St-Ag:1–17 and 11% and 19% for ExoA.
Anstead et al. [35] found a varied accuracy employing five
different serological methods for antibody research in a multicenter
study, obtaining good results of specificity and NPV, despite of
oscillating PPV and sensitivity, different from those of Doğru
et al. [37] who found high PPV, NPV and sensitivity of
serology to ExoA, ELA and AP, but a high number of patients
with negative culture presenting high antibody titers, resulting
in low specificity.4. Discussion
This review gathered studies for a period of almost 40 years and
evaluated the utility of the antibody detection againstP. aeruginosa
antigens, a technique that has been studied as an alternative
to the current gold standard [35], the culture of respiratory
samples, which many times is performed through oropharyn-
geal swab and has several limitations [19], such as no
representative samples and occurrence of false-negative
results. This makes it crucial to detect early this bacteria in
order to avoid chronic infection and the resulting infection
progress [38,39].
Infection is commonly distinguished from colonization based
on immune and inflammatory responses, despite of inflammatory
response being common in CF. P. aeruginosa isolation in
respiratory samples does not necessarily indicate infection unless
there is a specific antibody response [20].
There is a great diversity of results in the studies analyzed
herein due to different methodologies, casuistries, times of
follow-up, and antigens used. Several studies highlight the
Table 3
Main methods used for detection of serum antibodies to P. aeruginosa in CF patients.
Method Type of assay Measures Examples
Enzyme-linked immunosorbent
assay (ELISA)
Immunoenzymatic Antigens or antibodies linked to a conjugate labeled
with an enzyme
Immunoglobulins and exoproteins
Western blot Protein separation followed by
immunoenzymatic assay
Antibodies against whole cell proteins Immunoglobulins
Radioimmunoassay (RIA) Immunoradiometric Antigens or antibodies labeled with radioisotopes Immunoglobulins and exoproteins
Crossed immune electrophoresis (CIE) Immunoprecipitation Precipitates resulting from the antigen–antibody
interaction
Precipitins
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measure for early P. aeruginosa detection, before microbio-
logical culture, in a time period varying from 5 to 30 months
[17,22,27,31]. The emergence of the immune response differs
according to each employed antigen, being the response to TTSS
proteins apparently earlier during the acute stage of infection,Table 4
Studies evaluating P. aeruginosa ELISA serology accuracy for different ant
NI: not informed.
a Patients submitted to BAL.
b Patients of the Australasian Bronchoalveolar Lavage Trial.declining as the infection progresses to the chronic stage [21,24].
The response to commercialized antigens (ExoA, ELA and AP—
M15 Mediagnost and St-Ag:1–17 — Statens Serum Institute)
showed good sensitivity and specificity [16,25,26,29,32]. The
response to St-Ag:1–17 occurred several months before the first
microbiological isolation, and the response to ExoA, ELA and APigens.
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since they are antigens regulated by quorum-sensing, i.e., need
a higher microorganism density to lead to the response
[13,32,40]. Antibodies to ELA appeared later (a mean of
41.1 months after the first microbiological isolation), being
more frequent in chronic infected patients, and may be useful
in the diagnostic of chronic infection [22,27]. The enhance-
ment of antibodies against ExoA and AP was associated with
the risk of recurrent P. aeruginosa isolation, so patients with
new acquisition of the pathogen may benefit from a close
monitoring of these antibodies [35]. In some cases, antibody
response can be transitory and, especially in children between
4 and 6 years, only one positive result may not represent chronic
infection or intermittent colonization [26]. Da Silva Filho et al. [30]
tested serology for ExoA, ELA, and AP, and compared it to PCR
andmicrobiological culture, finding that the association of the three
methods guided to the higher positivity percentage, being PCR the
one with higher positivity, but with no statistical significance. As
the study was not longitudinal, they could not take any other
conclusions, despite considering that serology should not be
useful to detect intermittent colonization cases, since the immune
response appears just in persistent or recurrent infection cases.
Douglas et al. [34] questioned the use of serology forP. aeruginosa
detection, but recognized that they used BAL culture as the gold
standard, and this method may lead to false positive results due to
contamination of upper airways and false negatives, resulting from
inappropriate samples [7]. In general, good accuracy measures are
shown by most studies, being serology for antibody detection
recommended as a diagnostic tool in the follow-up routine. It is
recommended, for non-colonized patients (in the microbiological
point of view), that the antibody monitoring be performed at least
annually for patients with negative culture and more frequently for
intermittent patients [25,27].
It is observed that there is a relationship between enhanced
antibody titers against P. aeruginosa antigens (St-Ag:1–17
[12], cell wall antigens [17] and ExoA [22]) and clinical
status, where patients presented lower ventilatory function, worst
Shwachman–Kulczyki score and severe radiographic alterations,
even in a period of almost 6 months before the first positive
P. aeruginosa culture [22], which is associated with the worst
prognosis and deterioration of pulmonary function [41]. There is a
proposal to associate the X-ray score and antibody titers for the
early diagnosis of P. aeruginosa infection [22]. Pressler et al. [32]
compared two ELISA tests to distinguish between intermittent
colonization and chronic infection. Patients with intermittent
culture and higher antibody titers against the St-Ag:1–17 may be
indicative of status change to chronically infected, being this
response earlier than to ExoA, ELA, and AP. Culture limitations
can make it difficult to identify chronically infected patients,
which, without immunological results, can be wrongly classified
as intermittent or even free of infection or never colonized
[9,30,32].
With regard to the response of antibody titers against infection
treatment, there was decreasing IgG titers to cell wall antigens and
to St-Ag:1–17 after i.v. [14,17,23], and inhalatory [29] antibiotic
treatments, with survival of patients who presented lower titers
being longer, in chronic infection cases [23], and enhanced titers inpatients in which eradication therapy failed [29]. When there
is a rise in the antibody titers, early antibiotic treatment must
be considered, since in 80% of the cases it is possible to
prevent chronic infection [21,29,32,42]. However, there is a
greater consensus that serology results must be confirmed by a
longitudinal follow-up, employing other auxiliary diagnostic
resources, and thus, should not be adopted as the only criterion
for diagnosis and treatment [28,30,31,33,43].
5. Conclusions
Although we found a low number of papers addressing the
diagnostic utility of detection of serum antibodies toP. aeruginosa,
we recognized consistent results, especially in the studies using the
serology for antibody detection against St-Ag:1–17, since the
researches employing this antigen had continuity over the course
of 30 years, with significant casuistries and early P. aeruginosa
detection, with good clinical correlation when compared with
longitudinal microbiological culture (prospective microbiological
analysis). We also highlight the utility of the ELISA technique for
anti-pseudomonal antibodies, which is a simple and commercially
available method and does not demand great investments. The
accuracy values (sensitivity, specificity, PPV and NPV) of the
ELISA technique remain controversial, because of the diversity
of antigens, cut-off values and casuistries employed; however,
considering that most studies showed a good correlation between
anti-pseudomonal antibody titers and clinical status, both for
success in eradication and for progress to chronic infection or
exacerbations, this resource may be useful in early detection or to
alert the clinician to seek for other evidences of P. aeruginosa
colonization or infection, and also to provide parameters to
evaluate the colonization/infection status [44,45]. An impor-
tant gap is the lack of studies comparing serology, microbi-
ological culture and molecular resources for search of evidences
of P. aeruginosa presence, like PCR and RT-PCR of respiratory
samples, mainly in longitudinal studies with significant casuist-
ries, to better elucidate some apparently inconsistent results of
serology. The evidences of potential utility of P. aeruginosa
serology, technical and financial viability, give support to suggest
the incorporation of this diagnostic tool in the follow-up routine
of CF patients in the effort to reduce the prevalence of chronic
P. aeruginosa infection and for best understanding of the
colonization/infection process.References
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